+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2027

  • PDF Icon

    Report

  • 210 Pages
  • July 2023
  • Region: Global
  • IHR Insights
  • ID: 5850089
10% Free customization
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Natural Killer (NK) Cells Therapeutics market refers to the pharmaceutical products and therapies aimed at utilizing and enhancing the functions of natural killer cells for therapeutic purposes. Natural killer cells are a type of immune cell that plays a crucial role in the body's innate immune response against infected or cancerous cells. Natural killer cells have demonstrated strong potential in cancer immunotherapy. They are capable of recognizing and eliminating tumor cells without prior sensitization, making them an attractive option for cancer treatment. The ability of NK cells to target a wide range of tumor types and their potential for combination therapy with other immune checkpoint inhibitors or monoclonal antibodies drive the demand for Natural Killer (NK) Cells Therapeutics. On the other hand, the higher costs incurred in the therapies and adverse side effects of natural killer cells therapeutics are key factors likely to restrict the market growth. Natural Killer Cells Therapeutics Market is likely to grow at a rate of 8.5% CAGR by 2027.

Natural Killer Cells Therapeutics Market by Therapeutics

  • Natural killer cell therapies
  • NK cell-directed antibodies

Natural Killer Cells Therapeutics Market by Application

  • Cancer
  • Gastrointestinal diseases
  • Immunoproliferative disorders

Natural Killer Cells Therapeutics Market by End User

  • Research centers and institutes
  • Hospitals and clinics

Natural Killer Cells Therapeutics Market by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Natural Killer cell-based therapies are being investigated and developed for various medical conditions, including:

Cancer Immunotherapy: Natural Killer cells have the ability to recognize and eliminate cancer cells. NK cell-based immunotherapies, such as adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) Natural Killer cell therapy, are being developed to enhance the anti-tumor activity of Natural Killer cells. These therapies involve isolating and expanding NK cells from a donor or the patient's own cells, modifying them to improve their targeting capabilities, and then reinfusing them into the patient to target and kill cancer cells.

Infectious Diseases: NK cells also play a role in the defense against viral infections, such as hepatitis B and C, HIV, and cytomegalovirus (CMV). Therapeutic approaches that aim to enhance NK cell function or stimulate their antiviral activity are being explored for the treatment of these infections.

Autoimmune Disorders: In certain autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), the balance between Natural Killer cell activation and regulation is disrupted. Strategies to modulate Natural Killer cell activity and restore immune balance are being investigated as potential therapeutic options for these conditions.

The NK cells therapeutics market is driven by the increasing understanding of the role of NK cells in immune responses and the growing interest in harnessing their therapeutic potential. Pharmaceutical companies and biotechnology firms are actively involved in research and development efforts to optimize natural killer cells isolation, expansion, and manipulation techniques.

The major leading companies of the natural killer cells therapeutics market are Affimed N.V., Celgene Corporation, Fate Therapeutics Inc., Fortress Biotech, Glycostem Therapeutics Bv, Nkarta Therapeutics, Inc., Nkt Therapeutics Inc., Innate Pharma Sa, Nantkwest Inc, and Ziopharm Oncology Inc.

The market also includes healthcare providers, hospitals, and specialized treatment centers that administer NK cell-based therapies. Diagnostic laboratories may be involved in assessing patients' immune profiles and identifying suitable candidates for NK cell therapies.

As research progresses and clinical trials continue, the market is expected to witness advancements in manufacturing processes, cell engineering techniques, and the development of combination therapies. Challenges such as the optimization of NK cell expansion and persistence, reducing potential side effects, and ensuring long-term therapeutic efficacy are areas of active investigation in the field of natural killer cells therapeutics.

It's important to note that the Natural Killer Cells Therapeutics market is still evolving, and regulatory approvals for specific Natural Killer cell-based therapies may vary by region.

Key reasons to purchase the report:

  • This report depicts the accurate evaluation of the acoustic insulation market size and its share in the parent market
  • Exact estimations of forthcoming trends and changes in market dynamics are also included in this report
This report provides the growth of the acoustic insulation market industry across North America, Asia Pacific, Europe, rest of the world.
  • Comprehensive analysis of the market's competitive outlook and detailed information of vendors is depicted in the study.
  • Exclusive details of factors which will challenge the growth of Natural Killer Cells Therapeutics market players.

Table of Contents

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Therapeutics: Market Size & Analysis
5.1. NK Cell Therapies
5.2. NK Cell Directed Antibodies
6. Application: Market Size & Analysis
6.1. Cancer
6.2. Gastrointestinal Diseases
6.3. Immunoproliferative Disorders
7. End User: Market Size & Analysis
7.1. Research Centers& Institutes
7.2. Hospitals
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. NKARTA THERAPEUTICS, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ZIOPHARM ONCOLOGY INC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. GLYCOSTEM THERAPEUTICS BV
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. FATE THERAPEUTICS INC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. FORTRESS BIOTECH
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. NANTKWEST INC.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. INNATE PHARMA SA.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. NKT THERAPEUTICS INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. CELGENE CORPORATION
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. AFFIMED N.V
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

Companies Mentioned

  • NKARTA THERAPEUTICS, INC.
  • ZIOPHARM ONCOLOGY INC
  • GLYCOSTEM THERAPEUTICS BV
  • FATE THERAPEUTICS INC.
  • FORTRESS BIOTECH
  • NANTKWEST INC.
  • INNATE PHARMA SA.
  • NKT THERAPEUTICS INC
  • CELGENE CORPORATION
  • AFFIMED N.V